At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
06990 SKB BIO
Market Closed 10-23 16:08:09
460.400
+12.600
+2.81%
High469.000Low440.400Vol1.22M
Open448.000D1 Closing447.800Amplitude6.39%
Mkt Cap110.04BTradable Cap81.49BTotal Shares239.00M
T/O560.25MT/O Rate0.69%Tradable Shares177.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Movement Alert｜SKB BIO Rises 3.89% in Regular Trading, Innovation Drug Overseas Licensing Momentum Supports Sentiment
Market Focus  ·  10-23 10:23
Movement Alert｜SKB BIO Rises 3.89% in Regular Trading, Innovation Drug Overseas Licensing Momentum Supports Sentiment
Movement Alert｜SKB BIO Falls 3.17% in Regular Trading, Innovative Drug Sector Pullback Weighed on Sentiment
Market Focus  ·  10-22 10:40
Movement Alert｜SKB BIO Falls 3.17% in Regular Trading, Innovative Drug Sector Pullback Weighed on Sentiment
Movement Alert｜SKB BIO Intraday Rise 3.72% in Regular Trading, Innovative Drug Sentiment Lifted by Strong China Out-licensing Data
Market Focus  ·  10-21
Movement Alert｜SKB BIO Intraday Rise 3.72% in Regular Trading, Innovative Drug Sentiment Lifted by Strong China Out-licensing Data
How Clinical Trial Updates At Kelun Biotech Share Price Story Has Changed Its Investment Story
Simply Wall St.  ·  10-19
How Clinical Trial Updates At Kelun Biotech Share Price Story Has Changed Its Investment Story
Sichuan Kelun Biotech Biopharmaceutical (SEHK:6990) Showcased Phase III ADC Data, Is It A Bargain?
Simply Wall St.  ·  10-17
Sichuan Kelun Biotech Biopharmaceutical (SEHK:6990) Showcased Phase III ADC Data, Is It A Bargain?
Movement Alert｜SKB BIO Intraday Rise 4.47% in Regular Trading, Institutional Stake Increase and Biotech Sector Strength Support Sentiment
Market Focus  ·  10-16
Movement Alert｜SKB BIO Intraday Rise 4.47% in Regular Trading, Institutional Stake Increase and Biotech Sector Strength Support Sentiment
JPMorgan: ESMO Catalysts Set to Validate China's Homegrown Biotech Innovation, Top Picks Kelun-Biotech and Innovent Bio
Deep News  ·  10-14
JPMorgan: ESMO Catalysts Set to Validate China's Homegrown Biotech Innovation, Top Picks Kelun-Biotech and Innovent Bio
HK Movers | Biotech Stocks Fall Broadly; AKESO Down Over 10%, ZAI LAB Down Over 8%
Tiger Newspress  ·  10-14
HK Movers | Biotech Stocks Fall Broadly; AKESO Down Over 10%, ZAI LAB Down Over 8%
Kelun-Biotech to Debut Phase 3 TroFuse-005 Sac-TMT Endometrial Cancer Data at ESMO 2026 Presidential Symposium
Reuters  ·  10-13
Kelun-Biotech to Debut Phase 3 TroFuse-005 Sac-TMT Endometrial Cancer Data at ESMO 2026 Presidential Symposium
China Universal Asset Management Raises Stake in SKB BIO (06990) by 62,000 Shares at Approximately HK$454.07 Each
Stock News  ·  10-13
China Universal Asset Management Raises Stake in SKB BIO (06990) by 62,000 Shares at Approximately HK$454.07 Each
SKB BIO: Gexin Liu Disposes of Shares, Long Position Falls to 49.28%
HK Disclosure  ·  10-09
SKB BIO: Gexin Liu Disposes of Shares, Long Position Falls to 49.28%
SKB BIO: Gexin Liu Disposes of Shares, Long Position Falls to 49.32%
HK Disclosure  ·  10-09
SKB BIO: Gexin Liu Disposes of Shares, Long Position Falls to 49.32%
JPMorgan Unfazed by Rising Rates Impact on China Healthcare, Remains Bullish on Biotech and CXO
Stock News  ·  10-06
JPMorgan Unfazed by Rising Rates Impact on China Healthcare, Remains Bullish on Biotech and CXO
Movement Alert｜SKB BIO Falls 3.45% in Regular Trading, Biotech Sector Under Broad Selling Pressure
Market Focus  ·  10-02
Movement Alert｜SKB BIO Falls 3.45% in Regular Trading, Biotech Sector Under Broad Selling Pressure
Movement Alert｜SKB BIO Rises 3.42% in Regular Trading, TROP2 ADC Sac-TMT Studies Selected as LBA at ESMO Conference Amid Sector Rally
Market Focus  ·  09-30
Movement Alert｜SKB BIO Rises 3.42% in Regular Trading, TROP2 ADC Sac-TMT Studies Selected as LBA at ESMO Conference Amid Sector Rally
SKB BIO: DFZQ Acquires Shares, Long Position Rises to 5.0%
HK Disclosure  ·  09-29
SKB BIO: DFZQ Acquires Shares, Long Position Rises to 5.0%
Movement Alert｜SKB BIO Rises 4.17% in Regular Trading, Multiple Studies Selected as Late-Breaking Abstracts at ESMO Plus Biotech Sector Resonance
Market Focus  ·  09-29
Movement Alert｜SKB BIO Rises 4.17% in Regular Trading, Multiple Studies Selected as Late-Breaking Abstracts at ESMO Plus Biotech Sector Resonance
SKB BIO (06990): 汇添富基金管理股份有限公司 Acquires Shares, Long Position Rises to 5.0%
HK Disclosure  ·  09-24
SKB BIO (06990): 汇添富基金管理股份有限公司 Acquires Shares, Long Position Rises to 5.0%
Kelun-Biotech Says Phase 3 OptiTROP-Lung06 Sacituzumab Tirumotecan Plus Pembrolizumab Trial Wins ESMO 2026 Late-Breaker Slot
Reuters  ·  09-22
Kelun-Biotech Says Phase 3 OptiTROP-Lung06 Sacituzumab Tirumotecan Plus Pembrolizumab Trial Wins ESMO 2026 Late-Breaker Slot
Citi Highlights Policy Boost for Innovative Drugs and Medical Devices, Names Key Sector Picks
Stock News  ·  09-21
Citi Highlights Policy Boost for Innovative Drugs and Medical Devices, Names Key Sector Picks

Introduction

Company Name.
SKB BIO
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of drugs. The Company is mainly engaged in the research and development, manufacturing and commercialization of novel drugs in oncology, immunology and other therapeutic areas. The Company's products are antibody drug conjugates (ADCs) SKB264, A166 and others. The Company's products are mainly used for the treatment of breast cancer, non-small cell lung cancer, gastrointestinal cancer and other diseases.
Issue price:
--